Lp-PLA2 generates pro-inflammatory lipid products that amplify vascular inflammation and plaque activity.

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as PLA2G7, is an enzyme primarily bound to low-density lipoprotein (LDL) in human plasma. It serves as a specific biomarker for vascular inflammation and is intricately involved in the biochemical progression of atherosclerosis.

Mechanistic pathways of lipid hydrolysis

Lp-PLA2 functions as a highly specialized scavenger of oxidatively damaged lipids. Unlike other members of the phospholipase family, it demonstrates a unique substrate preference for oxidized phospholipids (OxPLs) rather than unmodified ones.

• Substrate Specificity: The enzyme specifically recognizes and targets phospholipids on the LDL surface that have undergone oxidative modification, particularly those with truncated or polar polyunsaturated fatty acyl chains at the sn-2 position (e.g., 9-oxononanoyl chains).
• Catalytic Reaction: Lp-PLA2 hydrolyzes the sn-2 ester bond of these oxidized phospholipids. This reaction releases two potent bioactive products: lysophosphatidylcholine (LysoPC) and oxidized non-esterified fatty acids (OxNEFAs).
• Enzymatic Activity: While the enzyme can also degrade platelet-activating factor (PAF), its dominant role in the context of vascular disease is the processing of oxidized phosphatidylcholine species (OxPC), as confirmed by lipidomic and mass spectrometry (LC-ESI-MS) studies.

Impact on vascular inflammation and plaque activity

While the initial hydrolysis might appear to be a detoxification step (removing reactive OxPLs), the resulting metabolites—especially LysoPC—are primary drivers of chronic vascular inflammation.

• Pro-inflammatory Signaling: LysoPC acts as a potent mediator that increases the expression of endothelial adhesion molecules (such as ICAM-1 and VCAM-1) and stimulates the production of cytokines like TNF-α and IL-6.
• Plaque Vulnerability: The accumulation of these hydrolysis products facilitates the recruitment of macrophages into the arterial wall, contributing to necrotic core expansion and the thinning of the fibrous cap. This process effectively converts stable atherosclerotic lesions into unstable, high-risk "vulnerable" plaques.
• Clinical Significance: Elevated Lp-PLA2 activity levels are consistently associated with increased plaque activity and are independent predictors of major adverse cardiovascular events (MACE), including myocardial infarction and acute coronary syndrome. Large-scale observational studies demonstrate that high Lp-PLA2 levels correlate with the presence of complex, lipid-rich necrotic cores.

Bottom line

The claim is strongly supported by biochemical and clinical evidence. Lp-PLA2 selectively hydrolyzes oxidized phospholipids on LDL to generate lysophosphatidylcholine and oxidized fatty acids, which directly amplify vascular inflammation and promote the transition to unstable atherosclerotic plaques.